Disease is a network, 
so we discover drugs that way

Our technology

A laboratory built to monitor 
the transcriptome

Chemical Barcoding
Chemical Barcoding
In order to match a potential therapeutic intervention to disease barcode, we needed to build a chemical barcode using transcriptomics. To date, global mRNA sequencing is too expensive to profile the vast potential of chemistry that might become a drug. To solve this we've developed our GRETA™ platform, a dramatic technology shift in biomedical research that allows us to sequence global mRNA 300-fold cheaper and faster than traditional technologies. Arpeggio has created the world's largest database of chemotranscriptomics, discovering an entirely new chemical grammar.
Disease Barcoding
Every cell in our body has the same genome, but a hair 
follicle looks a lot different than a neuron. This is due to a 
cell’s transcriptome: the set of more than 20,000 mRNAs uniquely oriented to define a cell’s identity. No surprise, the transcriptome changes dramatically in diseases like breast cancer or chronic kidney disease.  We use CRISPR to engineer disease models and estimate a transcriptomic barcode.
Generative AI and DRUG-NETTM
Advances in machine learning like Generative Adversarial Networks or Transformer Architectures have created the current generative AI revolution. At Arpeggio, we’re using AI to generate drug-like molecules guided by the transcriptome, developing Structure-Activity Relationships with RNA fingerprints directly. Saving time and cost, our DRUG-NETTM stack predicts a potential drug's toxic side effect before we even make or test it.  
Our Pipeline

Chronic disease

99.5% of adults over fifty will have a chronic disease by 2040. We're working on developing a pipeline of potential
drugs to tackle drug resistance in cancer, 
chronic kidney disease, and neurodegeneration.